B&B Tools AB
SWF:NOVN ISIN:CH0012005267
Mit einem Umsatz von rund 2,8 Milliarden Euro im Jahr 2007 und einem Marktanteil von elf Prozent ist Novartis die umsatzstärkste Pharmaunternehmensgruppe im deutschen Gesundheitsmarkt.
Sprache wählen
News
Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * New data, updated since ASCO, show time without tumor growth now reaches nearly 5 months with RAD001 versus 1.9 months with placebo * One quarter of patients in trial remained progression-free beyond ten months of treatment * RAD001 is first drug to show significant benefit after failure of initial therapy, Sutent® or Nexavar®**, with potential to address unmet medical need
Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * Coartem achieves high cure rates in studies[1],[2] and since 2001 has helped save an estimated 500,000 lives * Priority review by FDA underscores urgency of stopping malaria - a key goal of US President's Malaria Initiative * Working with international community, Novartis has supplied more than 195 million treatments to malaria-endemic countries without profit
###
55,180 COMPANY PROFILE VIEWS
- Diese Seite wurde besucht: (letzten 7 Tagen: 98) (letzten 30 Tagen: 424) (seit Veröffentlichung: 19648)
